Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas

Lazaridou, Ingrid; Ram‐Wolff, Caroline; Bouaziz, Jean‐David; Bégon, É.; Battistella, Maxime; Rivet, Jacqueline; Bagot, Martine; Masson, Adèle de

doi:10.2340/00015555-3576

Cited by 24 publications

(42 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, pruritus in both atopic and nonatopic individuals has been reported to improve with dupilumab for various types of chronic refractory itch, such as lichen planus, genital itching, uremic itching, idiopathic itching, and eosinophilic dermatosis of hematological malignancies [160][161][162]. In addition, isolated case reports show the beneficial effect of dupilumab in various skin disorders and diseases affecting the skin, such as eosinophilic annular erythema (with the resolution of all lesions and pruritus [164,165]), keloids [166], pruritic epidermolysis bullosa [167], hypereosinophilic syndrome [168], and cutaneous T-cell lymphoma (mycosis fungoides) [169].…”

Section: Pruritusmentioning

confidence: 99%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

Recent advances in understanding T2 inflammation have broadened the diseases in which T2 inflammation can be involved. Dupilumab is a recently developed monoclonal antibody blocking the signaling of both IL-4 and IL13, two crucial cytokines of the T2 responses. New possible indications are increasingly exploring. Among them are skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, among other several cutaneous diseases. Also, respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy are two more research fields. Here we review the published data and clinical trials about the use of dupilumab in these disorders.

show abstract

Section: Pruritusmentioning

confidence: 99%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

show abstract

“…Some real-world data indicate that dupilumab was not so effective in the real world as in clinical trials. Because there is overlap in the clinical appearance of moderate-to-severe AD and mycosis fungoides ( Silverberg, 2020 ), patients with mycosis fungoides can be misdiagnosed with AD ( Chiba et al., 2019 ; Lazaridou et al., 2020 ; Newsom et al., 2021 ). Furthermore, some clinical features of allergic contact dermatitis and psoriasis are similar to those of AD.…”

Section: Effectiveness and Safety Of Dupilumab For Ad In The Real Worldmentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…3,4 Recently, a limited set of CTCL cases occurring during or after treatment with dupilumab for AD was reported along with some observations of established CTCL worsening after initial symptomatic improvement (Table I). [5][6][7][8][9][10] Our case differs from these previous cases of CTCL occurring in allegedly benign chronic conditions treated by dupilumab by its histopathologic subset, never specifically reported in this setting to date. However, overall it raises a similar hypothesis, including the selection and the promotion of a preexisting, initially inconspicuous dupilumabresistant CD30 1 T-cell clone through a dupilumabinduced depletion of tumor-infiltrating lymphocytes with tumor suppressive activity contributing to the emergence of the neoplastic clone.…”

Section: Discussionmentioning

confidence: 86%